Search | Clinical Trials Finder

Conditions: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions: Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Chronic Liver Disease, Healthy Participants
Interventions: AZD2389, Midazolam, Caffeine, Bupropion; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Tobacco Dependence
Interventions: bupropion + nicotine gum, Active bupropion-Placebo gum, Placebo bupropion-Placebo gum; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Depressive Disorder
Interventions: Bupropion HCl; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 25 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Obesity
Interventions: Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Naltrexone-Bupropion Combination, Orlistat; Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depression
Interventions: Escitalopram, Bupropion; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nicotine Dependence, Schizophrenia
Interventions: NRT, Bupropion SR 150mg bid, Relapse Prevention-Oriented Cognitive Behavioral Therapy; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 88
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions: Lamotrigine and Bupropion, Placebo; Drug
Lead sponsor: Dent Neuroscience Research Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Amherst, New York

Conditions: Depression, Major Depressive Disorder, Unipolar Depression
Interventions: Wellbutrin, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Smoking Cessation
Interventions: Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more

Conditions: Obesity, Overweight
Interventions: NB32, PBO, Weight Management Program; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 45 Years and older
Enrollment: 8,910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 224
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more

Conditions: Acute Coronary Syndrome, Depression
Interventions: Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care; Behavioral · Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
Interventions: Placebo, Auvelity; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Participants
Interventions: Fluconazole, Bupropion, Itraconazole, BMS-986235; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Breast Cancer, Major Depressive Disorder
Interventions: bupropion extended release (Wellbutrin XL); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Methamphetamine Use Disorder
Interventions: naltrexone plus bupropion; Drug
Lead sponsor: Walter Ling; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Los Angeles, California • Honolulu, Hawaii • Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Bupropion XL; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Postpartum Smoking Relapse
Interventions: Bupropion Extended Release Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nicotine Dependence, Tobacco Use
Interventions: Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain; Drug · Behavioral
Lead sponsor: Mark Vander Weg; Other
Eligibility: 18 Years to 99 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Alcoholism, Smoking
Interventions: bupropion (Wellbutrin); Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 25 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Amphetamine-Related Disorders
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Binge-eating Disorder, Obesity
Interventions: NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo; Drug · Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Bupropion Alone or Combined With Nicotine Gum

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Lamotrigine and Bupropion for Meniere's Disease

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Comparison of Depression Interventions After Acute Coronary Syndrome

Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Connectivity Affecting the Antidepressant REsponse Study

Bupropion for the Prevention of Postpartum Smoking Relapse

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

Bupropion as a Smoking Cessation Aid in Alcoholics

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use